Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance

Autor: Eva Wolf, Christoph Boesecke, Annamaria Balogh, Helen Bidner, Christiane Cordes, Hans Heiken, Ivanka Krznaric, Tim Kümmerle, Hans-Jürgen Stellbrink, Jochen Schneider, Christoph D. Spinner, the DUALIS Study Group
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-5 (2021)
Druh dokumentu: article
ISSN: 1742-6405
DOI: 10.1186/s12981-021-00384-6
Popis: Abstract Objective The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically suppressed people living with HIV (PLWH). We analyzed virologic outcomes with respect to treatment history and HIV drug resistance. Design Post hoc analysis of a randomized trial. Methods Main inclusion criteria were an HIV RNA level
Databáze: Directory of Open Access Journals